Literature DB >> 23846287

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study.

Matteo Vassallo1, Brigitte Dunais, Jacques Durant, Helene Carsenti-Dellamonica, Alexandra Harvey-Langton, Jacqueline Cottalorda, Michel Ticchioni, Muriel Laffon, Christine Lebrun-Frenay, Pierre Dellamonica, Christian Pradier.   

Abstract

Contributory factors to HIV-associated neurocognitive disorders (HAND) have been shown to include age, co-morbid infections, medication toxicity, virological, genetic and vascular mechanisms, as well as microbial translocation of lipopolysaccharide (LPS), which is suspected to trigger monocyte activation and increase trafficking of infected cells into the brain. In this study, our aim was to assess the degree of neurocognitive impairment in a group of randomly selected HIV-infected patients and investigate potential risk factors, including LPS plasma levels. Furthermore, we evaluated the relevance of LPS as a potential marker for screening patients with mild neurocognitive impairment. LPS plasma levels were compared among patients with HAND and those with no HAND. As LPS has also been shown to be elevated in hepatitis C co-infection, the analysis was stratified according to the presence or not of hepatitis C virus (HCV) co-infection. Differences between groups were evaluated using chi-square tests and Kruskal-Wallis non-parametric tests. Stepwise logistic regression was performed to identify independent risk factors for HAND in the subgroups of HCV-positive and negative patients. A p value <0.05 was considered significant. Analyses were conducted using SPSS® software. From December 2007 to July 2009, 179 patients were tested (mean age 44, 73 % male, 87 % on treatment, 30 % HCV co-infected, median CD4 504/ml and 67 % with viral load below 40 copies/ml). HAND was identified in 40/179 patients (22 %), the majority displaying asymptomatic neurocognitive impairment or mild neurocognitive disorder. Univariate analysis showed that age, illicit drug use, hepatitis C co-infection, prior AIDS-defining events, CD4/CD8 ratio and LPS plasma levels were significantly associated with HAND. The median LPS level was 98.2 pg/ml in the non-HAND group versus 116.1 pg/ml in the HAND group (p < 0.014). No differences were found in LPS values between subgroups of impairment. There was a clear association between LPS levels and HAND in the HCV-positive group (p = 0.036), while there was none in the HCV-negative group (p = 0.502). No difference in degree of hepatic fibrosis was found between the HAND and non-HAND groups. In conclusion, LPS levels were associated with HAND in the HCV-positive group, while, in the HCV-negative group, age and pro-viral DNA were the only variables independently associated with HAND. There was no difference in degree of liver disease as predicted by score of fibrosis between HAND and non-HAND groups. The role of HCV co-infection and higher LPS levels in the pathogenesis of HAND in patients with viral suppression on treatment requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846287     DOI: 10.1007/s13365-013-0181-y

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  22 in total

Review 1.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

2.  Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.

Authors:  Audrey L French; Charlesnika T Evans; Denis M Agniel; Mardge H Cohen; Marion Peters; Alan L Landay; Seema N Desai
Journal:  J Infect Dis       Date:  2013-05-17       Impact factor: 5.226

3.  Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients.

Authors:  H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke
Journal:  Gut       Date:  2008-10-20       Impact factor: 23.059

4.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

5.  Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Authors:  Emmanouil Papasavvas; Maxwell Pistilli; Griffin Reynolds; Robert Bucki; Livio Azzoni; Jihed Chehimi; Paul A Janmey; Mark J DiNubile; Joe Ondercin; Jay R Kostman; Karam C Mounzer; Luis J Montaner
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

6.  Effects of coinfection with HIV and hepatitis C virus on the nervous system.

Authors:  H Aaron Aronow; Alan J Weston; Benjamin B Pezeshki; Tadd S Lazarus
Journal:  AIDS Read       Date:  2008-01

7.  Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment.

Authors:  Hans Rempel; Bing Sun; Cyrus Calosing; Linda Abadjian; Alexander Monto; Lynn Pulliam
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

8.  Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  Giulia Marchetti; Paola Nasta; Francesca Bai; Francesca Gatti; Giusi Maria Bellistrì; Camilla Tincati; Federica Borghi; Giampiero Carosi; Massimo Puoti; Antonella d'Arminio Monforte
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 9.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

10.  Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.

Authors:  Petronela Ancuta; Anupa Kamat; Kevin J Kunstman; Eun-Young Kim; Patrick Autissier; Alysse Wurcel; Tauheed Zaman; David Stone; Megan Mefford; Susan Morgello; Elyse J Singer; Steven M Wolinsky; Dana Gabuzda
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  16 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

Review 2.  Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 3.  Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.

Authors:  Anna C Hearps; Genevieve E Martin; Reena Rajasuriar; Suzanne M Crowe
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

4.  Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.

Authors:  Khutso M Mothapo; J Ten Oever; P Koopmans; F F Stelma; S Burm; J Bajramovic; M M Verbeek; M G Olde Rikkert; M G Netea; G Koopman; A J van der Ven
Journal:  J Neurovirol       Date:  2016-11-23       Impact factor: 2.643

5.  A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.

Authors:  Matteo Vassallo; R Fabre; J Durant; C Lebrun-Frenay; H Joly; M Ticchioni; F DeSalvador; A Harvey-Langton; B Dunais; M Laffon; J Cottalorda; P Dellamonica; C Pradier
Journal:  J Neurovirol       Date:  2016-11-04       Impact factor: 2.643

6.  HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis.

Authors:  Palsamy Periyasamy; Annadurai Thangaraj; Venkata Sunil Bendi; Shilpa Buch
Journal:  Brain Behav Immun       Date:  2019-03-11       Impact factor: 7.217

7.  Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.

Authors:  Jacqueline Rosenthal; William Tyor
Journal:  J Neurovirol       Date:  2019-03-13       Impact factor: 2.643

8.  Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders.

Authors:  Alexander J Gill; Colleen E Kovacsics; Stephanie A Cross; Patricia J Vance; Lorraine L Kolson; Kelly L Jordan-Sciutto; Benjamin B Gelman; Dennis L Kolson
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

9.  HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy.

Authors:  Annadurai Thangaraj; Palsamy Periyasamy; Ke Liao; Venkata Sunil Bendi; Shannon Callen; Gurudutt Pendyala; Shilpa Buch
Journal:  Autophagy       Date:  2018-07-26       Impact factor: 16.016

10.  Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury.

Authors:  Wei Jiang; Zhenwu Luo; Sophie Stephenson; Hong Li; Clara Di Germanio; Philip J Norris; Dietmar Fuchs; Henrik Zetterberg; Magnus Gisslen; Richard W Price
Journal:  J Infect Dis       Date:  2021-05-20       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.